Floatz logo

Regorafenib

Thymic Carcinoma

Istituto Clinico HumanitasSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Thymic Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 2B
Fludarabine
Beijing Biotech
Phase 2B
azd6244
National Cancer Institute (NCI)
Phase 2B
CYCLOSPORIN A
Roswell Park Cancer Institute
Phase 2B
Busulphan
Roswell Park Cancer Institute
Phase 2B

View all 26 →

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →